參考文獻(xiàn)/References:
[1] OINONEN R,FRANSSILA K,TEERENHOVI L,et al. Mantle cell lymphoma:clinical features,treatment and prognosis of 94 patients[J].European Journal of Cancer,1998,34(3):329-336.
[2] SABATTINI E,BACCI F,SAGRAMOSO C,et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview[J].Pathologica,2010,102(3): 83-87.
[3] VOSE J M. Mantle cell lymphoma:2017 update on diagnosis,risk-stratification,and clinical management[J].American Journal of Hematology,2017,92(8):806-813.
[4] KLEIHUES P,SOBIN L H. World Health Organization classification of tumors[J].Cancer,2000,88(12):2887.
[5] BERTONI F,PONZONI M. The cellular origin of mantle cell lymphoma[J].Int J Biochem Cell Biol,2007,39(10):1747-1753.
[6] MIAO Y,LIN P,SAKSENA A,et al. CD5-negative mantle cell lymphoma: clinicopathologic correlations and outcome in 58 patients[J].Am J Surg Pathol,2019,43(8):1052-1060.
[7] ROBAK T,HUANG H Q,JIN J,et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma[J].New England Journal of Medicine,2015,372(10):944-953.
[8] MADDOCKS K,CHRISTIAN B,JAGLOWSKI S,et al. A phase 1/1b study of rituximab,bendamustine,and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma[J].Blood,2015,125(2):242-248.